RSC Advances · 2018 · 29 citations · 28 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyChemotherapyDrug DiscoveryAnticancer Prodrug DesignCombination ChemotherapyCytotoxic ChemotherapyOncology PharmacologyAnticancer ActivityAnticancer ChemotherapyBiological Evaluation ReportChemo-selectivityChemotherapeutic Prodrug DesignHistone Deacetylase TargetsLevofloxacin-based TherapyTubulin Polymerization Inhibitors
A strategy to develop chemotherapy agents by combining two complimentary chemo-active groups into a single molecule may have higher efficacy and fewer side effects than that of single-target drugs. In this article, we describe the synthesis and evaluation of a series of novel dual-acting levofloxacin-HDACi conjugates to target both histone deacetylase (HDAC) and tubulin polymerization. These bifunctional conjugates exhibited potent inhibitory activities against HDACs and tubulin polymerization. In docking analysis provides a structural basis for HDACs inhibition activities. Moreover, these conjugates showed selective anticancer activity that is more potent against MCF-7 compared to other four cancer cells A549, HepG2, PC-3, HeLa, but they had no toxicity toward normal cells.
28
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Christopher J. Millard, Peter J. Watson, Ivana Celardo et al. · Molecular Cell · 2013 · 397 citations · Full text